Please use this identifier to cite or link to this item:
Title: Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)
Authors: Vaz-da-Silva, Manuel 
Nunes, Teresa 
Rocha, José F. 
Falcão, Amílcar 
Almeida, Luis 
Soares-da-Silva, Patricio 
Keywords: Etamicastat
Issue Date: 1-Jun-2011
Publisher: Adis International
Citation: VAZ-DA-SILVA, Manuel [et al.] - Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). "Drugs in R&D". ISSN 1174-5886. Vol. 11, nº 2 (2011) p. 127-136
Serial title, monograph or event: Drugs in R&D
Volume: 11
Issue: 2
Abstract: Background Etamicastat is a novel, potent, and reversible peripheral dopamine-β-hydroxylase inhibitor that has been administered orally at doses up to 600 mg once daily for 10 days to male healthy volunteers and appears to be well tolerated. Objective The aim of this study was to investigate the effect of food on the pharmacokinetics of etamicastat. Material and Methods A single-center, open-label, randomized, two-way crossover study in 12 healthy male subjects was performed. Subjects were administered a single dose of etamicastat 200 mg following either a standard high-fat and high-calorie content meal (test) or 10 hours of fasting (reference). The statistical method for testing the effect of food on the pharmacokinetic parameters of interest was based upon the 90% confidence interval (CI) for the test/reference geometric mean ratio (GMR). The parameters of interest were maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) from time zero to the last measurable concentration (AUClast), and AUC from time zero to infinity (AUC∞). Bioequivalence was assumed when the 90% CI fell within the recommended acceptance interval (80, 125). Results Etamicastat Cmax, AUClast, and AUC∞ were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition. Etamicastat test/reference GMR was 72.27% (90% CI 64.98, 80.38) for Cmax, 93.59% (90% CI 89.28, 98.11) for AUClast, and 96.47% (90% CI 91.67, 101.53) for AUC∞. Time to Cmax was prolonged by the presence of food (p < 0.001). The Cmax, AUClast, and AUC∞ values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition. BIA 5-961 test/reference GMR was 62.42% (90% CI 56.77, 68.63) for Cmax, 79.41% (90% CI 56.77, 68.63) for AUClast, and 83.47% (90% CI 76.62, 90.93) for AUC∞. A total of six mild to moderate unspecific adverse events were reported by four subjects. There was no clinically significant abnormality in laboratory assessments. Conclusion Etamicastat was well tolerated. The Cmax of etamicastat decreased 28% following oral administration of etamicastat in the presence of food, while AUC remained within the pre-defined acceptance interval. The delay in absorption and decrease in peak exposure of etamicastat is not clinically significant, and therefore etamicastat could be administered without regard to meals.
ISSN: 1174-5886
DOI: 10.5414/cpp46564
Rights: openAccess
Appears in Collections:FFUC- Artigos em Revistas Internacionais
I&D CNC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
Effect of Food on the Pharmacokinetic.pdf293.92 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on Nov 24, 2021

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.